cells, effectively reduced cell surface Npn-1, and promoted its internalization. Use of soluble forms of Npn-1 or VEGF receptor-1 to block VEGF 165 binding to Npn-1 or to VEGF receptors provided evidence that surface Npn-1 and VEGF receptors are required for VEGF 165 -induced Npn-1 internalization. Sema3A also reduced cell surface Npn-1 in endothelial cells and promoted its internalization, but required a higher concentration than VEGF 165 . These results demonstrate that preferential receptor binding and internalization by a ligand are mechanisms by which the common receptor Npn-1 can play an essential role in prioritizing conflicting signals.
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INTRODUCTION
The vascular and nervous systems have a tree-like branched structure originating from a center and reaching all tissues. Often vessels and nerves run parallel, suggesting that they are guided by common guidance mechanisms. Indeed, there is evidence that axonal guidance cues are also involved in blood vessel formation. VEGF, an essential regulator of vascular development, has recently been shown to regulate neuronal development [1] [2] [3] [4] .
Class 3 semaphorins, a family of six secreted glycoproteins that includes
Sema3A-3F, function as axonal chemorepellents for growth cones during neuronal development [5] [6] [7] . Their receptors are composed of a ligand-binding chain consisting of
Neuropilins, and a signal transducing chain consisting of plexins 8 . Except for Sema3E, which directly binds to Plexin-D1 9 , Sema3A, 3B, 3C, and 3D need to bind to Neuropilin-1 (Npn-1) or Npn-2 to signal [10] [11] [12] [13] [14] . Class 3 semaphorins utilize distinct combinations of neuropilins and plexins as their receptor system 13, [15] [16] [17] ; Sema3A uses Npn-1-Plexin-A1, A2, or A4 16, 17 . Recent studies in mice with targeted deletions of semaphorin signal components have revealed an essential role of semaphorin signaling in normal vascular development 9, 15, 18 .
The VEGF-family of proteins is required for angiogenesis during development and after birth, and contributes to neuronal growth, immune regulation, and hematopoiesis 3, [19] [20] [21] . Npn-1 serves as a VEGF-A isotype-specific receptor 22 165 binding to VEGF receptor-2 (VEGFR-2/KDR/Flk-1) and VEGF 165 activity 24 . VEGF-B isoforms (VEGF-B 167 and VEGF-B 186 ) and placenta growth factor-2 (PlGF-2) bind to Npn-1 and activate VEGFR-1 (Flt-1) [25] [26] [27] . The VEGFlike protein from orf virus NZ2 binds to Npn-1 and activates VEGFR-2 28 .
Due to its ability to bind various ligands, Npn-1 appears to serve as a "hub"
receptor for different ligands. The multiple domain structure of Npn-1 extracellular domain may explain how Npn-1 interacts with various ligands. Npn-1 has a large extracellular domain of 860 amino acids, which consists of 3 subdomains, a1, a2 (CUB), b1, b2 (coagulation factor V/VIII), and c (MAM) domains. Sema3A binds to Npn-1 via a1a2b1 domains, whereas VEGF 165 binds via b1b2 domains 29 . Heparin and PlGF-2 also bind to the b1b2 domain 27 . Consistent with Npn-1 playing multiple roles, Npn-1 deficient mice are embryonically lethal and display severe abnormalities in the nervous and cardiovascular systems 30, 31 . Endothelial-cell-specific npn-1-null mice showed severe vascular defects 32 . In vitro, Npn-1 plays a role in cell-to-cell adhesion 33 .
Npn-1 mediates distinct functions by choice of ligand and ligand-specific signal transducer: the semaphorin-Npn-1 complex uses plexin to signal, whereas the VEGF- 
METHODS

Cytokines and Reagents.
Recombinant human VEGF 165 , VEGF 121 , VEGF-B 167 , VEGF-C, FGF-2, chimeric human Sema3A/Fc, soluble rat Npn-1/Fc (srNpn-1/Fc), human VEGFR-1/Fc, and human B7-1/Fc were from R&D Systems. Porcine heparin sodium salt and bovine fibronectin were from Sigma.
Cells and Cell Culture.
Primary human umbilical vein endothelial cells (HUVEC) were prepared from umbilical cord and cultured as previously described 36 . HUVEC were used between passages 2 and 5. The human stromal cell line HS-5 (ATCC) was maintained in DMEM with 10% fetal bovine serum (FBS); the rat pheochromocytoma cell line PC-12 (ATCC) was maintained on fibronectin-coated dishes in DMEM with 10% FBS and 10% horse serum.
Endothelial cell survival, adhesion and proliferation assays
HUVEC were starved by overnight incubation in MEDIUM199 (Cellgro) with 1% FBS, and then cultured (7, 
Lamellipodia spreading assay
Four-chamber glass slides (LAB-TEK, Nalge Nunc International) were coated with 10 μg/mL poly-L-lysine (Sigma) in PBS. HUVEC (40,000/chamber) were added to the chambers in MEDIUM199 with 1% FBS and 2 μg/mL heparin; Sema3A alone or with VEGF 165 or VEGF 121 were added to the cultures. After 30 minutes at 37°C, the medium was replaced with 4% wt/vol paraformaldehyde for 15 minutes fixation. After removal of the plastic chambers, the glass slide was washed with PBS (3x) and mounted. Four non-overlapping fields were counted at low-power magnification (X40) to obtain an average ratio of the number of cells with lamellipodia spreading/the total number of adherent cells (40 to 90 cells/field). A cell was considered positive for spreading if it displayed lamellipodia in at least three-fourths of the periphery.
Endothelial cell retraction assay.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Four-chamber glass slides were coated with 5 μg/ml fibronectin in PBS. HUVEC (15,000/chamber) were grown in HUVEC culture medium for 16 hours, washed with MEDIUM199 with 10% FBS and 2 μg/mL heparin and incubated in the same medium with Sema3A (2 μg/mL or as indicated). After fixation with 4% wt/vol paraformaldehyde, slides were washed with PBS, and four non-overlapping fields were observed to obtain an average retraction score (30 to 60 cells/field). Retraction scores were assigned blindly as described in the text.
Cord formation assay
The assay was performed as described 36 . Cells were starved overnight in MEDIUM199 
Laser confocal microscopic analysis
Endothelial cells on glass chamber slides coated with 5 μg/mL fibronectin were incubated (MEDIUM199 with 10% FBS and 2 μg/mL heparin) with 25 ng/mL VEGF 165 or 2 μg/mL Sema3A at 37°C for the indicated times. The medium was replaced with 4% 
Statistical analysis.
Results are expressed as means ± SD. Student's t-test was applied to evaluate group differences; a p-value of < 0.05 was considered significant.
RESULTS
Sema3A inhibits endothelial cell attachment, survival and proliferation; blocking by VEGF 165 We examined the effects of Sema3A on endothelial cell attachment, survival and growth, and tested whether VEGF 165 , a VEGF-A isoform that binds Npn-1 24 , modifies these activities of Sema3A. Previously, Sema3A was reported to inhibit endothelial cell adhesion to extracellular matrix 18 . As shown in Fig. 1A , we found that Sema3A also inhibits endothelial cell adhesion to tissue culture wells, in the absence of protein coating.
This inhibition was blocked by VEGF 165 , but not by VEGF 121 , a VEGF-A isoform that lacks the Npn-1 binding domain 24 . Since previous studies concluded that attachment is critical to endothelial cell survival 37 , we examined whether reduced endothelial cell attachment correlated with decreased survival. In the same cultures, we measured first cell survival using a colorimetric assay, and after removal of non-adherent cells, we measured cell attachment (NIH-image analysis). We found that Sema3A dosedependently reduces endothelial cell viability after 16 hours incubation in culture medium with 1% FBS (Fig.1B, We also examined the effects of Sema3A on endothelial cell proliferation after 3-day culture. As expected ( 1C ). These results demonstrate that Sema3A inhibits endothelial cell attachment, survival and proliferation, and that VEGF 165 , but not VEGF 121 , can counter these functions of Sema3A.
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We examined in detail cell attachment inhibition by Sema3A, and tested whether Sema3A inhibits the initial step of endothelial cell spreading or rather promotes cell retraction and detachment once spreading has occurred. Endothelial cells usually spread their lamellipodia for firm adherence to poly-L-lysine-coated glass surfaces within 30 minutes ( Fig. 2A left panel) . Lamellipodia spreading by endothelial cells is not observed on uncoated glass surfaces (not shown). In the presence of Sema3A (2 μg/mL), endothelial cell attached to the poly-L-lysine-coated surfaces, but displayed virtually no spreading of lamellipodia ( Fig. 2A right panel) . This effect was dependent upon Sema3A concentration (Fig. 2B ). VEGF 165 (25 ng/mL) significantly reduced this effect of Sema3A, whereas VEGF 121 (25 ng/mL) was ineffective (Fig. 2C) . upper left). After incubation with Sema3A for 1 hour, the endothelial cells displayed retracted lamellipodia to a various degree (Fig. 2D lower) , which was reflected by more sharp cell boundaries ( Fig. 2D upper right) . Similar Sema3A-induced lamellipodia retraction was noted in endothelial cells cultured on poly-L-lysine-coated glass surfaces (data not shown). To quantify lamellipodia retraction, we established a scoring system (Fig. 2D lower panels) . By blindly scoring at least 120 cells from 4 fields, we obtained 165 to Npn-1 (Fig. 3A) .
Based on these results, we examined whether VEGF 165 interferes with the binding of Sema3A to Npn-1, with or without heparin (2 μg/mL). As shown in Fig. 3B, VEGF 165 dose-dependently inhibited the binding of Sema3A to Npn-1. However, even at the highest concentration tested (1,600 ng/mL), reduction by VEGF 165 was less than 50% with or without heparin. In the biological assays above ( Fig. 1 and 2 ), 25 ng/mL VEGF 165 inhibited almost completely the activities of Sema3A (1-2 μg/mL), whereas this concentration of VEGF 165 did not significantly inhibit the binding of Sema3A (2 μg/mL) to purified Npn-1. These results suggested that VEGF 165 inhibits Sema3A activity in endothelial cells by mechanisms other than simple binding competition for Npn-1.
VEGF 165 inhibits the binding of Sema3A to target cells
In the presence of VEGF 165 , Npn-1 forms a complex with VEGFR-2, which enhances the binding of VEGF 165 to VEGFR-2 22 . Also, Npn-1 forms a stable complex with Plexin-A1, and this complex has a higher affinity for Sema3A than does Npn-1 alone 41 . Since endothelial cells express Plexin-A1 and VEGFR-2 in addition to Npn-1 18 , we tested whether VEGF 165 can compete for Sema3A binding to the surface of endothelial cells.
FACS analysis showed that Sema3A/Fc bound to endothelial cell dose-dependently, whereas a control B7-1/Fc did not (Fig. 4A) . When added to cells together with VEGF 165 at 4°C for 1 hour, Sema3A/Fc (2 μg/mL) binding to cells was reduced by VEGF 165 dosedependently (Fig. 4B, top) . 12.5 ng/mL VEGF 165 
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approximately 50%. VEGF 121 , VEGF-B 167 , VEGF-C and FGF-2 (all at 100 ng/mL) failed to reduce Sema3A/Fc binding to endothelial cells (Fig. 4B) .
We examined Sema3A (2 μg/mL) binding to endothelial cells (1 hour at 4°C) after the cells were pre-incubated (25°C for 1 hour) with VEGF 165 (12.5 ng/mL).
VEGF 165 was not removed. Under these conditions, VEGF 165 at 12.5 ng/mL reduced Sema3A/Fc (2 μg/mL) binding to endothelial cells by approximately 80% (Fig. 4C, top) .
These results indicated that pre-incubation of cells with VEGF 165 at 25°C is more effective at reducing Sema3A binding than simultaneous addition of VEGF 165 Fig. 4D ) and rat pheochromocytoma PC12 cells (Fig. 4E) . These results indicate that VEGF 165 can inhibit the binding of Sema3A to cells of various lineages.
VEGF 165 reduces endothelial cell surface Npn-1 and induces its internalization
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To clarify the mechanisms by which VEGF 165 reduces the binding of Sema3A to target cells, we examined endothelial cell surface expression of Npn-1. Using FACS analysis, we found that 1hour pre-incubation at 25°C with VEGF 165 , but not VEGF 121, dosedependently reduced surface Npn-1 (Fig. 5A, left) . At the concentration of 12.5 ng/mL (0.3 nM), VEGF 165 reduced by approximately 50% Npn-1 levels detected on control cells. In parallel experiments, both VEGF 165 and VEGF 121 reduced surface VEGFR-2 (Fig. 5A, right) but did not affect surface CD31 in these cells (not shown). VEGF 165 also specifically reduced surface Npn-1 in HS-5 cell (not shown; the effect on rat PC12 cell could not be tested because the antibody fails to recognize rat Npn-1).
Since heparin is required for maximal binding of VEGF 165 to Npn-1, we examined the effect of heparin on VEGF 165 (250 ng/mL)-induced reduction of Npn-1 on endothelial cell. We found that heparin enhances VEGF 165 -induced reduction of surface Npn-1, with maximal Npn-1 reduction achieved at heparin concentration of 80 ng/mL (Fig. 5B) . We also examined the effect of temperature on VEGF 165 -induced reduction of surface Npn-1. At 4°C, levels of surface Npn-1 reached a plateau after 15 minutes, whereas Npn-1 continued to decrease at 25°C and 37°C (Fig. 5C ). The reduction of Npn-1 was somewhat more rapid and linear at 37°C than seen at 25°C. When endothelial cells were incubated with VEGF 165 (25 ng/mL) at 37°C for 30 hours, levels of surface Npn-1 were approximately 75% lower than those measured on endothelial cells cultured under the same conditions with 25 ng/mL VEGF 121 or FGF-2 (Fig. 5D ). This time and temperature-dependent pattern of surface Npn-1 decrease induced by VEGF 165 suggested either that Npn-1 undergoes structural change, which renders it undetectable under these conditions, or that levels of surface Npn-1 decrease.
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We examined whether internalization contributes to the reduction of surface Npn-1 by VEGF 165 . Therefore, we compared the effects of VEGF 165 on cell surface and total cell-associated levels of Npn-1. By FACS analysis, VEGF 165 (25 and 250 ng/mL, 25°C 1 hour) reduced substantially levels of surface Npn-1, but to a much lower degree levels of Npn-1 detected after cell permeabilization, which include cell surface and intracellular Npn-1 (Fig. 5E) , suggesting that internalization contributed to the reduction of surface Npn-1 levels by VEGF 165 . Using confocal microscopy, we traced Npn-1 distribution in endothelial cells after VEGF 165 stimulation (Fig. 5F ). After 5 minutes incubation with VEGF 165 (25 ng/mL, 37°C), Npn-1 was detectable more intensely at the endothelial cell rim, especially on lamellipodia, whereas after 30 minutes Npn-1 was detectable more intensely in the cytoplasm at the perinuclear region with a dot-like distribution. After 60 minutes, Npn-1 staining was detected almost exclusively at the perinuclear region.
VEGF 121 and FGF-2 did not induce such changes (not shown). Based on these results, we conclude that VEGF 165 reduces cell surface Npn-1, al least in part, by promoting its internalization.
Characterization of requirements for VEGF-induced reduction of surface Npn-1
The experiments above indicated that VEGF 165 inhibits Sema3A function in endothelial cells ( Fig. 1 and 2 ) by competing with Sema3A for binding to cell surface receptors (Fig.   4 ) and inducing Npn-1 internalization (Fig. 5) . Since VEGF 165 is ineffective at directly competing with Sema3A for binding to Npn-1 (Fig. 3B) , we examined the potential contribution of VEGF receptors present on endothelial cells. First, we compared a soluble rat Npn-1 (srNpn-1) and a soluble VEGFR-1 (sVEGFR-1) for their ability to For personal use only. on September 14, 2017. by guest www.bloodjournal.org From compete with VEGF 165 binding to immobilized Npn-1. srNpn-1, which is expected to serve as a direct competitor for VEGF 165 , inhibited binding of VEGF 165 to immobilized Npn-1 (Fig. 6A, left) . By contrast, sVEGFR-1, which interferes with VEGF binding to both VEGFR-1 and VEGFR-2 44 , minimally affected the binding of VEGF 165 to immobilized Npn-1, even at the highest VEGFR-1 concentration (3.2 μg/mL) tested (Fig.   6A, right) . Thus, sVEGFR-1 does not directly compete with VEGF 165 binding to Npn-1.
We then compared the effects of srNpn-1 and sVEGFR-1 on VEGF 165 -induced reduction of cell surface Npn-1. To detect human endothelial cell surface Npn-1, we used the anti-human Npn-1 mAb AD5-17F6. This anti-human Npn-1 mAb specifically recognizes human Npn-1 and does not cross-react with rat Npn-1 because excess amounts of srNpn-1 (5 μg/mL) did not significantly alter recognition of human Npn-1 by this antibody (Fig. 6B, upper left) . The species specificity of this antibody to human Npn-1 contrasts with the lack of species-specificity of human VEGF 165 and Sema3A, which can both bind to srNpn-1 (Fig. 3A) . Taking advantage of this anti-human Npn-1 mAb for detection of surface Npn-1 on human endothelial cells, we found that srNpn-1 dosedependently blocked VEGF 165 -induced reduction of cell surface Npn-1 (Fig. 6B, lower left). These results indicated that a direct interaction of VEGF 165 with membrane-bound Npn-1 is essential for VEGF 165 to reduce cell surface Npn-1. By confocal microscopy we found that srNpn-1 reduced VEGF 165 -induced internalization of Npn-1, indicating that binding to cell surface Npn-1 is also essential for VEGF 165 to promote Npn-1 internalization (Fig. 6C ).
To examine whether interaction with VEGFR-1 and/or VEGFR-2 is necessary for VEGF 165 to reduce cell surface Npn-1 and promote Npn-1 internalization, we used
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From sVEGFR-1, which does not compete for VEGF 165 binding to Npn-1 (Fig. 6A ), but neutralizes VEGF bioactivity by competing for VEGF binding to VEGFR-1 and VEGFR-2 44 . Endothelial cells were incubated with VEGF 165 (25 ng/mL) plus sVEGFR-1 (0-800 ng/mL). Dose-dependently, sVEGFR-1 blocked VEGF 165 -induced reduction of cell surface Npn-1 (Fig. 6B, lower right) , whereas a control protein (B7-1/Fc) had no effect (Fig. 6B, upper right) . In addition, by confocal microscopy, we found that sVEGFR-1 reduced VEGF 165 -induced internalization of Npn-1 (Fig. 6C) . These results indicated that VEGF 165 must interact with endothelial cell surface VEGFR-1 and/or VEGFR-2 to effectively reduce cell surface Npn-1 and promote its internalization, perhaps by bridging VEGFR-1 and/or VEGFR-2 with Npn-1.
Finally, we investigated the effect of sVEGFR-1 on functional assays in which
Sema3A promotes endothelial cell retraction and VEGF 165 reduces this effect. Dosedependently, sVEGFR-1 reduced VEGF 165 inhibition of the Sema3A-induced retraction of endothelial cells (Fig. 6D ). This result is consistent with the observations above that sVEGFR-1 reduces Npn-1 internalization induced by VEGF 165 , thereby enhancing surface Npn-1 available for binding to Sema3A.
Sema3A-induces Npn-1 internalization
It was reported that Sema3A could induce Npn-1 endocytosis in the COS7 cell line, which co-express Npn-1 and the L1 cell adhesion molecule 45 . We examined whether
Sema3A can also induce Npn-1 internalization in primary endothelial cells. We found that Sema3A dose-dependently reduced endothelial cell surface Npn-1 (Fig. 7A) , and that approximately 1 μg/mL (4 nM) Sema3A was required to achieve a 50% reduction in Sema3A is required to achieve levels of surface Npn-1 reduction comparable to those induced by VEGF 165 under the same experimental conditions (Fig.5A) . As expected, srNpn-1 blocked reduction of surface Npn-1 induced by Sema3A, whereas sVEGFR-1 was ineffective (data not shown). By using confocal microscopy, we confirmed that Sema3A could induce Npn-1 internalization (Fig. 7B) . After 5 minutes stimulation with Sema3A, Npn-1 accumulated mainly in the cell-to-cell junctional regions, and after 30 minutes Npn-1 accumulated in the cytoplasmic region similar to the pattern noted after stimulation with VEGF 165 . These results demonstrate that Sema3A can induce Npn-1 internalization in endothelial cells.
DISCUSSION
We show that Sema3A inhibits endothelial cell lamellipodia formation, attachment, survival and growth, and that VEGF 165 counters these activities of Sema3A.
We further show that this functional competition between Sema3A and VEGF 165 is attributable to preferential binding of VEGF 165 to target cells and internalization of the shared receptor Npn-1. This potency difference at promoting Npn-1 internalization can dictate a priority for Npn-1 usage by VEGF 165 over Sema3A, effectively blocking Sema3A function. Thus, our results demonstrate that control of surface levels of the common receptor is a critical mechanism for functional prioritization among ligands that share a receptor. Sema3A could also reduce surface levels of Npn-1 by promoting its internalization, but required a higher concentration than VEGF 165 at reducing Npn-1 surface levels. The conclusion that Sema3A is less potent than VEGF 165 We established a requirement for linkage between cell surface Npn-1 and VEGFR-1 or VEGFR-2 in VEGF 165 -induced Npn-1 internalization. This conclusion comes from the observation that soluble VEGFR-1 extracellular domain, which does not interfere with the binding of VEGF 165 to Npn-1 (Fig. 6A ) but competes for VEGF 165 binding to VEGFR-1 or VEGFR-2 44 , blocked VEGF 165 -induced down-regulation of surface Npn-1 (Fig. 6B) . Consistent with this conclusion, VEGF 121 , which does not bind Npn-1 but binds to VEGFRs, did not affect Npn-1 levels. VEGFRs are subject to endocytosis and subsequent ubiquitination by the E3 ubiquitin ligase/multi-adaptor protein Cbl 46, 47 . It will be important to establish whether Npn-1 is also degraded.
Interestingly, we observed PEST sequences for protein degradation in the region of amino acid 823-840 of human Npn-1 48 .
In addition to VEGF 165 , PlGF-2 is known to inhibit Sema3A-induced growth cone collapse in dorsal root ganglion neurons 49 . PlGF-2 has the potential to link Npn-1 to VEGF receptors, and thus may down-regulate Npn-1 by the same mechanism of VEGF 165 . FGF family members can also interact with Npn-1 39 . However, our results
show that FGF-2 did not change Npn-1 levels and did not inhibit endothelial cell retraction induced by Sema3A. Thus, FGF-2 may not bridge Npn-1 to FGF receptor.
Also, VEGF 165 could inhibit other class 3 semaphorin family members that use the common receptor Npn-1. If so, our observations could explain why VEGF 165 , but not 21 VEGF 121 , inhibited Sema3B-induced apoptosis in lung and breast cancers 50 . In addition, since VEGF 165 can bind to Npn-2 51 besides Npn-1, it will be interesting to examine whether VEGF 165 can induce internalization of Npn-2 and thereby inhibit Npn-2-mediated effects of class 3 semaphorins.
Npn-1 is known to serve as a cell-to-cell adhesion molecule 33 
